NOV-002 mentioned on Research Knowledgebase – Dr Alberto Montero Oncologist

Dr. Montero’s primary interest is in development of effective immunotherapeutic strategies for the treatment of solid tumors (in particular in breast cancer and hepatobiliary malignancies). Dr. Montero has a special interest in understanding how tumor derived factors lead to the accumulation of myeloid derived suppressor cells (MDSC) and what bearing circulating MDSCs have on regulatory T-cells, prognosis, and on effectiveness of cancer vaccines or other immunotherapeutic strategies.

Dr. Montero’s ongoing research includes a novel glutathione mimetic (NOV-002) which is part of an investigator initiated phase II neoadjuvant trial at the University of Miami which thusfar in 17 patients with HER-2 unamplified breast cancer has shown to have an approximate 40% near pathologic and complete response rate (pCR) when combined with standard anthracycline-taxane based chemotherapy. In comparison to previously published trials, expected breast and node pCR rates for a similar chemotherapy regimen in HER-2 negative patients would be approximately 10-20%. Dr. Montero and colleagues have shown that NOV-002 has an immunomodulatory effect in vivo which may be an important mechanism of action. Currently, Dr. Montero is investigating the effects of NOV-002 on MDSC and dendritic cells in preclinical models as well as in correlative studies from collected blood from an ongoing phase II trial.

Selected Cancer-Related Publications

Salem ML, Diaz-Montero CM, Al-Khami AA, El-Naggar SA, Naga O, Montero AJ, Khafagy A, Cole DJ. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol 182:2030-40, 2009. PubMed link

Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58(1):49-59, 2009. PubMed link

Diaz-Montero CM, El Naggar S, Al Khami A, El Naggar R, Montero AJ, Cole DJ, Salem ML. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol Immunother 57(4):563-72, 2008. PubMed link

Jiang Y, Ming L, Montero AJ, Kimchi E, Nikfarjam M, Staveley-O’Carroll KF. Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors. Gastrointest Cancer Res 2:245-50, 2008. PubMed link

Gudena V, Montero AJ, Glück S. Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther Clin Risk Manag 4:1157-64, 2008. PubMed link

For full description of Multidisciplinary Research Program(s), Tumor Immunobiology Program.
Back to Research Knowledgebase

The material in this press release comes from the originating research organization. Content may be edited for style and length. Have a question? Let us know.


One email, each morning, with our latest posts. From medical research to space news. Environment to energy. Technology to physics.

Thank you for subscribing.

Something went wrong.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.